Immunotherapy for Alzheimer’s Disease
A special issue of Life (ISSN 2075-1729). This special issue belongs to the section "Medical Research".
Deadline for manuscript submissions: closed (30 October 2021) | Viewed by 398
Special Issue Editors
Interests: regulation of the immune response; vaccine design; phage-based vaccines; virus-like-particle vaccines; protein vaccines; Alzheimer’s disease immunotherapy; induction of immune responses to self-antigens; correlates of vaccine efficacy; signaling in T-cell development and activation; T-cell receptor repertoire in coeliac disease; T-cell receptor repertoire of antigen-specific T-cell lines; modeling of biological phenomena: X chromosome inactivation; pairing of homologous chromosomes; chromatin organization
Special Issue Information
Dear Colleagues,
Immunotherapy for Alzheimer's disease has been investigated for over 20 years.
β-amyloid (Aβ) and tau proteins are considered the most promising targets to treat Alzheimer's disease. Several active and passive immunotherapies targeting these proteins are currently in clinical trials.
Antibodies against β-amyloid can slowly reduce the amyloid load in the brain and affect cognition. The concentration of antibodies, their fine specificity, and other qualitative features can affect the outcome of active and passive immunotherapies. Correlates of efficacy, however, are still elusive. Active immunotherapy faces the challenge of inducing consistent, robust, and durable responses against specific conformations of β-amyloid.
Inflammation plays an important role in Alzheimer's disease pathogenesis. Non-antigen-specific immunotherapies, which specifically target neuroinflammation, are being developed.
Importantly, different subgroups of patients, with different genetic risk factors, at different stages of the disease or bearing different strains of aggregated Aβ or tau may respond differently to immunotherapy.
In this Special Issue, we welcome reviews, short reviews, and original research articles on immunotherapy for Alzheimer's disease.
Dr. Antonella Prisco
Dr. Francesca Mantile
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Life is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Alzheimer’s disease
- vaccines
- passive immunotherapy
- Beta-amyloid
- Tau
